LAUSR

We have come to realize that T cell-centered immunotherapy is a promising approach for patients with hematological malignancies and may result in a disease cure. Hematological malignancies can downregulate target antigens and generate an immunosuppressive environment to escape the host immune response. It has become clear that the goal of immunotherapy is to exploit the patient immune system or confer immunity with T cells, NK cells, or monoclonal antibodies to kill tumor cells, and inducing and/or recovering T cell activation is a key aspect of these immunotherapies. Direct target immunotherapy by genetic engineering cytotoxicity T cells